BioSpace News Archive

Business

CytomX Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022

CytomX Therapeutics, Inc. today announced that it will report second quarter 2022 financial results on Thursday, August 4, 2022, after the close of U.S. markets.

July 28, 2022
·
2 min read
Business

Crown Bioscience Appoints Michael Prosser as Chief Business Officer and Illustrates Further Investment in Commercial Leadership

Crown Bioscience , a JSR Life Sciences company, announced today that it has restructured its commercial leadership team by creating a new Chief Business Officer (CBO) role and with additional investment in commercial talent.

July 28, 2022
·
3 min read
Business

Sunshine Biopharma Increases Support for Anti-Coronavirus Collaborative Research With the University of Arizona

Sunshine Biopharma Inc. today announced that it has agreed to provide additional resources to the University of Arizona R. Ken Coit College of Pharmacy for the purposes of accelerating the development of novel PLpro inhibitors currently underway.

July 28, 2022
·
3 min read
Pharm Country

Chemotherapy Drugs from “Rogue” Online Pharmacies Could Endanger Leukemia Patients, Suggests Research in JNCCN

Patients seeking to purchase chemotherapy drugs online face a confusing array of websites, over half of which potentially operate unsafely or illegally, finds a new study in the July 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network.

July 28, 2022
·
6 min read
Business

Wave Life Sciences to Webcast Conference Call of Second Quarter 2022 Financial Results on August 11, 2022

Wave Life Sciences Ltd. (Nasdaq: WVE), announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Thursday, August 11, 2022, to discuss the company’s second quarter 2022 financial results and provide a business update.

July 28, 2022
·
1 min read
Drug Development

NewAmsterdam Pharma Doses First Patient in Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia

NewAmsterdam Pharma (NewAmsterdam), a clinical-stage company focused on the research and development of transformative oral therapies for metabolic diseases, today announced the initiation of BROOKLYN, a pivotal Phase 3 clinical trial of obicetrapib.

July 28, 2022
·
14 min read
Genetown

Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDsPrescription Drug User Fee Act (PDUFA) target action date set for January 15, 2023

Acer Therapeutics Inc. (Nasdaq: ACER) (Acer) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), today announced the U.S. Food and Drug Administration (FDA) has accepted for review Acer’s resubmitted New Drug Application (NDA) for ACER-001 (sodium phenylbutyrate) for oral suspension for the treatment of patients with urea cycle disorders (UCDs).

July 28, 2022
·
7 min read
Business

Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease

Acer Therapeutics Inc. and RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to evaluate the efficacy and safety of ACER-001.

July 28, 2022
·
11 min read
BioCapital

Quoin Pharmaceuticals Announces Receipt of Constructive Scientific Advice from EMA for QRX003 Development in EuropeEMA Guidance Provides Clear Path Forward for Quoin’s Netherton Syndrome Product in Europe

Quoin Pharmaceuticals Ltd. announces that it has received comprehensive and constructive Scientific Advice from the European Medicines Agency (EMA) for the clinical and regulatory development of QRX003 in Europe.

July 28, 2022
·
4 min read
Business

CytoImmune Therapeutics and City of Hope Announce First Patient Dosed in a Phase 1 Trial Evaluating a Novel Off-the-Shelf Engineered Natural Killer Cellular Therapy for the Treatment of Non-Small Cell Lung Cancer

CytoImmune Therapeutics and City of Hope today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating CYTO-102.

July 28, 2022
·
5 min read